Welcome to the e-CCO Library!

P393: Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on infliximab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Yerlioglu*1, L. Cococcioni1, A. ElZein1, S. Sider1, S. Chadokufa1, R. Buckingham1, N. Shah1, A. Ocholi1, O. Borrelli1, F. Kiparissi1

Created: Friday, 22 February 2019, 9:41 AM
P393: Treatment patterns of patients with perianal fistulizing Crohn’s disease from a US administrative claims database
Year: 2021
Source: ECCO'21 Virtual
Authors: Cazzetta, S.(1);Chen, G.(2);Pedarla, V.(3);Null, K.(4);Rana Khan, Q.(1);Schwartz, D.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P394 Preoperative factors associated with prolonged postoperative in-hospital length of stay in patients with Crohn’s disease undergoing intestinal resection or strictureplasty
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Vinh Luong1, S. Dich Grandt2, I. Negoi3, S. Palubinskas2, A. El-Hussuna2

Created: Thursday, 30 January 2020, 10:12 AM
P394: A prospective analysis of body composition in patients with Inflammatory Bowel Disease and changes during biologic therapy
Year: 2022
Source: ECCO'22
Authors: Nguyen, A.(1);Burns, M.(2);Herath, M.(3);Holt, D.(2);Gibson, P.R.(4);Milat, F.(3);Ebeling, P.(5);Moore, G.(6);
Created: Friday, 11 February 2022, 3:52 PM
P394: Contribution of the CDEIS in the new therapeutic approach of Crohn's disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Sabbek*1, N. Elleuch2, A. Ben Slama2, E. Hammami2, H. Jaziri2, A. Braham2, S. Ajmi2, M. Ksiaa2, A. Jmaa2

Created: Friday, 22 February 2019, 9:41 AM
P394: Long-term perineal reoperation and wound healing after proctectomy or ileal pouch-anal anastomosis extirpation in patients with Inflammatory Bowel Disease – a retrospective multicentre study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Berghog, J.(1)*;Hermansson, M.(2);Risto, A.(3);Strömbäck, J.(4);Unger, D.(4);Gustafsson, H.(5);Hagavall, M.(6);Landerholm, K.(7);Buchwald, P.(8);Nordenvall, C.(9);Myrelid, P.(3);Block, M.(2);
Created: Friday, 14 July 2023, 11:05 AM
P394: Preoperative serum vedolizumab levels do not predict postoperative outcomes in inflammatory bowel disease (IBD)
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Lopez1, K. Zaghiyan1, G. Melmed1, D. McGovern1, A. Jain2, S. Targan1, P. Fleshner1*, C. Landers1

Created: Thursday, 21 February 2019, 9:14 AM
P394: Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Qiu Y.*1, Mao R.1, Zhang S.-h.2, Feng R.2, Zeng Z.-r.1, Chen M.-h.2

Created: Wednesday, 20 February 2019, 10:36 AM
P394: Psychosexual dysfunction in a cohort of Greek inflammatory bowel disease patients in clinical remission: preliminary results
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Xanthis*, K. Soufleris, E. Gavalas, P. Anyfanti, G. Chatzinakos, N. Grammatikos, A. Tsimperidis, O. Giouleme

Created: Friday, 22 February 2019, 9:49 AM
P394: Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Asser Karsdal, M.(1);Bay-Jensen, A.C.(1);Faber, K.N.(2);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);Festen, E.A.M.(2);K. Weersma, R.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P395 Management of pouch vaginal fistulae in ulcerative colitis: A 35-year experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. REZA1, E. Van Praag2, N. Iqbal1, C. Twum-Barima1, A. Hart3,4, S. Clark5,6, P. Tozer1,6

Created: Thursday, 30 January 2020, 10:12 AM
P395: Dermatological reactions associated with anti–TNF therapy in inflammatory bowel disease- an 12 year experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Bhandare*, R. Diyar, J. Taylor, J.K. Limdi

Created: Thursday, 21 February 2019, 9:14 AM
P395: Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sandborn W.J.1, Schreiber S.2, Tang M.T.3, Tatro A.R.3, Oh Y.S.*3, Maciuca R.3

Created: Wednesday, 20 February 2019, 10:36 AM
P395: Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Pai, R.(1);De Hertogh, G.(2);Reinisch, W.(3);Harpaz, N.(4);Feagan, B.(5);Agada, N.(6);Pollack, P.(6);Chan, L.S.(6);Protic, M.(6);Magro, F.(7);
Created: Wednesday, 2 June 2021, 4:12 PM
P395: Postoperative immunosuppressive therapies decrease the risk of second intestinal surgery in patients with Crohn’s disease: a retrospective cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

Y. Nagata*1,2, M. Esaki3, Y. Fuyuno2, Y. Okamoto2, S. Fujioka2, A. Hirano2, J. Umeno2, T. Torisu2, T. Moriyama2, S. Nakamura1, T. Kitazono2

Created: Friday, 22 February 2019, 9:41 AM
P395: Proactive Therapeutic Drug Monitoring May Reduce the Need for Combination Therapy in Inflammatory Bowel Disease Patients Treated with Infliximab
Year: 2022
Source: ECCO'22
Authors: Doherty, J.(1);Varley, R.(2);Dunne, C.(2);Mc Carthy, F.(1);Hartery, K.(1);Mc Kiernan , S.(1);Kevans, D.(1);
Created: Friday, 11 February 2022, 3:52 PM
P395: Real-life prospective experience with adalimumab in ulcerative colitis in Italy: preliminary results of a pilot study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Daperno*1, A. Armuzzi2, D. Pugliese2, A. Lavagna1, P. Gionchetti3, F. Rizzello3

Created: Friday, 22 February 2019, 9:49 AM
P395: Short-term clinical efficacy and safety of teduglutide for Crohn's disease patients with short bowel syndrome
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kaku, K.(1)*;Sato, T.(1);Takeuchi, J.(2);Uchino , M.(3);Fujihira, Y.(1); Shimizu, K.(1);Yokoyama, K.(1);Yagi , S.(1);Takashima, Y.(1);Ikenouchi, M.(1);Kojima, K.(1);Kawai, M.(1); Nagase , K.(1);Kamikozuru, K.(1);Yokoyama , Y.(1);Takagawa, T.(1); Ikeuchi, H.(3);Watanabe, K.(1);Shinzaki , S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C.A. Lee1, L. Acevedo1, D.A. Oh1, P. Baweja1, K. Gilder1, D. Han2, S. Jhee2, K. Komori1, S. Mullin1, T. Nguyen-Cleary1, K. Schmelzer2, Y. Tang1, J. Zhang1, J. Grundy1

Created: Thursday, 30 January 2020, 10:12 AM
P396: Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting
Year: 2021
Source: ECCO'21 Virtual
Authors: De Somer, T.(1);Deprez, N.(2);Baert, D.(1);Deceuninck, M.(3);Huys, I.(1);Mattens, V.(4);Sterckx, A.(4);Vanden Branden, S.(4);Vanderstraeten , E.(1);Vandervoort , J.(4);Van Heddegem, N.(1);Dewint, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM